The extracellular matrix (ECM) is a fundamental component of multicellular organisms that provides mechanical and chemical cues that orchestrate cellular and tissue organization and functions. Degradation, hyperproduction or alteration of the composition of the ECM cause or accompany numerous pathologies. Thus, a better characterization of ECM composition, metabolism, and biology can lead to the identification of novel prognostic and diagnostic markers and therapeutic opportunities. The development over the last few years of high-throughput ("omics") approaches has considerably accelerated the pace of discovery in life sciences. In this review, we describe new bioinformatic tools and experimental strategies for ECM research, and illustrate how these tools and approaches can be exploited to provide novel insights in our understanding of ECM biology. We also introduce a web platform "the matrisome project" and the database MatrisomeDB that compiles in silico and in vivo data on the matrisome, defined as the ensemble of genes encoding ECM and ECM-associated proteins. Finally, we present a first draft of an ECM atlas built by compiling proteomics data on the ECM composition of 14 different tissues and tumor types.
Introduction
The extracellular matrix (ECM), a complex meshwork of proteins, is a fundamental component of multicellular organisms. The ECM is the three-dimensional architectural scaffold that defines tissue boundaries and biomechanical properties [1] and cell polarity. It also serves as an adhesive substrate for cell migration and, by binding morphogens and growth factors [2] , can create concentration gradients for haptotactic migration [3, 4] or pattern formation [5] . Extracellular matrix proteins provide biochemical cues interpreted by cell surface receptors, such as the integrins [6] and initiate signaling cascades controlling cell survival, cell proliferation, differentiation and stem cell state [7, 8] .
Advances in genome sequencing have allowed one to trace the evolution of the ECM and have revealed that, although some domains or modules characteristic of ECM proteins existed in unicellular organisms, the elaboration of ECM proteins and ECMs appeared largely in metazoa [9, 10] . The multiplication and diversification of ECM proteins have accompanied major evolutionary innovations, in particular in the vertebrate phylum, including the appearance of a closed vascular system and of structures such as the neural crest, teeth, cartilage and bones [9, 10] . During development, ECM plays vital roles in stem cell niches and in guiding migration and polarity of cells and axonal projections and in morphogenesis and coherence of tissues.
Remodeling of ECM is essential during angiogenesis and branching morphogenesis of glands and in wound healing, as it is in cancer invasion [5] .
Mutations in ECM genes are causal of musculoskeletal, cardio-vascular, renal, ocular and skin, diseases [11] . In addition, excessive deposition or, conversely, destruction of the ECM can also lead to pathologies such as fibrosis or osteoarthritis [12] . ECM deposition (or desmoplasia) is a hallmark of tumor progression and has been used by pathologists as a marker of tumors with poor prognosis even long before the composition and the complexity of the ECM were uncovered. Recent studies from us and others have revealed that the ECM plays a functional role in tumor progression and dissemination [13, 14] .
We previously proposed that characterizing the global composition of the extracellular matrix proteome, or "matrisome" of normal and diseased tissues would lead to important discoveries. This proposition raised two important questions: how do we define the extracellular matrix and how can one study the composition of a compartment largely made of insoluble proteins? Here, we review the bioinformatic tools and experimental approaches that have been developed over the last few years to characterize the composition of extracellular matrices. We also introduce a web interface "the matrisome project" that hosts a novel database on ECM and ECM-associated genes and proteins, MatrisomeDB that compiles in silico and experimental resources and we illustrate Fig. 1 . Defining the matrisome. A. Definition of matrisome categories. The core matrisome comprises ECM glycoproteins, collagens and proteoglycans. Matrisome-associated proteins include ECM-affiliated proteins, ECM regulators and secreted factors [16, 17] . B. Pie charts represent the number of human genes encoding core matrisome and matrisome-associated proteins. "Hs" indicates genes in the human genome and "Mm", genes in the murine genome. their utility to analyze various "omics" datasets. Finally, we present here a first draft of an ECM atlas built by compiling proteomics data on the extracellular matrix of 14 different tissues and tumor types.
In silico definition of the matrisome Bioinformatic approach to define the matrisome In 1984, Martin and colleagues coined the term "matrisome" in the context of basement membranes to define "supramolecular complexes of matrix components which are the functional units of the forming extracellular matrix" [15] . In 2012, we proposed to extend the definition of this term to include not only all the genes encoding structural ECM components but also genes encoding proteins that can (or may) interact with or remodel the ECM [16] [17] [18] (Fig. 1A) . To define the matrisome, we devised a bioinformatic approach to screen the human and mouse proteomes (or any other genomes of interest) using defining features of ECM proteins such as presence of signal peptide and of protein domains characteristic of ECM proteins [16, 19] . We further curated manually the lists obtained computationally and, based on structural or functional features, distinguished core matrisome proteins from matrisome-associated proteins. The core matrisome comprises ECM glycoproteins, collagens and proteoglycans (Fig. 1A) (for reviews on each of these categories of proteins see [20] [21] [22] ). ECM-associated proteins include ECM-affiliated proteins, ECM regulators and secreted factors that may interact with core ECM proteins (Fig. 1A) [16] .
We note here that the criteria for assigning certain proteins to the matrisome categories can be debated. For example, the designation of the various secreted factors was deliberately inclusive since, although many of them are not known to associate with ECM, some clearly do and arguments can be adduced supporting the concept that many others do as well [2] . Equally, decisions such as where, or whether, to include some proteins containing short collagen triple helical domains or transmembrane segments are to some extent arbitrary. We view the current categorizations to be a working structure, subject to periodic revision in light of future discoveries.
Matrisome 2.0
The in silico definition of the matrisome relied on the interrogation of the protein database UniProt [23] using lists of domains from the InterPro [24] and SMART [25, 26] databases. The protein-centric lists originally defined were then turned into gene-centric lists using NCBI Entrez Gene as reference gene database [27] . Databases are, by nature, very dynamic and constantly updated. The release of a major update by UniProt in July 2014 with improved identification of isoforms, new knowledge (such as the identification of the first extracellular kinases [28] ) and discussions with colleagues have prompted us to update the original matrisome lists. This updated version of the matrisome (v2.0) comprises 1027 genes for the human genome and 1110 genes for the mouse genome (Fig. 1B) . These numbers are slightly smaller than the ones we reported in 2012; this is mainly due to better annotations of pseudogenes (now removed from the matrisome lists) and removal of duplicate entries in the newer UniProt database. It is worth noting that the relatively large difference in the number of genes encoding ECM regulators in human and mouse is mostly due to gene duplication of proteases such as ADAMs (a disintegrin and metalloprotease domain proteins) and serpins (serine protease inhibitors) in the mouse genome. In addition to updating the gene-centric lists, we have also updated the list of UniProt accession numbers associated with each matrisome gene. These updated matrisome lists as well as updated domain lists are available for download from the web interface we recently developed http://matrisomeproject.mit.edu [29] . This website hosts a new database, MatrisomeDB, that provides, for all human and murine matrisome genes, live cross-referencing to gene (HUGO Gene Nomenclature Committee [30] and Mouse Genome Informatics [31]) and protein (UniProt, InterPro) databases, and information on gene orthology. In addition to providing links to in silico resources on matrisome genes and proteins, MatrisomeDB also incorporates experimental proteomics data generated in the Hynes lab. Database users can now easily determine whether or not a given ECM protein has been detected by proteomics in the tissues and tumors profiled (see below).
Matrisome lists as annotation tools for big data
Identifying ECM signatures in gene and protein datasets
We previously noted that the matrisome lists and categories we defined are significantly more comprehensive than Gene Ontology's "Cellular Component" categories for data mining and for posing questions relevant to ECM biology, since ECM proteins are currently scattered in multiple GO categories and comingled with non-ECM proteins [17] . In order to further facilitate the use of categorical matrisome lists for annotating genomic, transcriptomic or proteomic outputs and identifying ECM signatures within datasets, we derived a collection of ten matrisome gene sets (Table 1 ) and implemented them into the Molecular Signatures Database maintained by the Broad Institute. In addition to allowing rapid annotation of large datasets and facilitating the identification of ECM signatures, these gene sets can now readily be used to conduct Gene Set Enrichment Analysis (GSEA) studies [32, 33] . GSEA is a computational method that determines whether an a priori defined set of genes (for example, the matrisome) shows statistically significant, concordant differences between two biological states. Hussenet, Orend and collaborators used such an approach to identify a matrisome signature enriched in the transcriptome of angiogenic vs non-angiogenic oncogenic pancreatic islets, which they termed the "angiomatrix" signature [34] . Once identified, ECM signatures (of a given tissue or disease state) can be further analyzed with pathway or interaction analysis tools such as MatrixDB [35, 36] .
ECM signatures can also be used to interrogate other publicly available datasets. For example, we compared the ECM signatures of primary colorectal tumors and their liver metastases defined by proteomic analysis of small numbers of patient samples, with gene expression data from four clinical studies representing over 200 patients and demonstrated the association of a subset of the ECM proteins, defined by proteomics, with tumor progression [37] .
Interrogating databases with matrisome lists
The two examples above illustrate the value of using limited experimental data on ECM genes or proteins to access and leverage the burgeoning pool of publicly available data from diverse modes of analysis. The development of high-throughput transcriptomics studies (microarray or RNAseq approaches) has been accompanied by the creation of databases to make the large body of data publicly available [38, 39] . Recent papers have also reported the first drafts of the human proteome [40] [41] [42] which has led to the development of a website http:// proteomicsdb.org. One can therefore use the matrisome list or sublists and ask which ECM genes or proteins are detected in which tissues, at which developmental stage(s), etc. As an example, we interrogated proteomicsDB with the list of 44 human collagen genes (Fig. 2) . Although the most abundant and ubiquitous collagens (type I, III, IV, VI) were detected in most tissue and cell proteomes, less abundant or rarer collagens were seen only in a few tissues or in none so far. This may reflect reality but could also result from the fact that most studies included in proteomicsDB were not designed to look specifically for ECM proteins and may well have missed them. The very nature of ECM proteins, which are often very large, highly glycosylated, cross-linked, and difficult to solubilize, has made biochemical analyses of the composition of extracellular matrices challenging.
Experimental characterization of in vivo matrisomes by proteomics
Technical challenges and proposed solutions
ECM protein enrichment
The profiling of the protein composition of extracellular matrices by mass spectrometry is dependent on the availability of methods that selectively enrich for ECM proteins. Taking advantage of the insolubility of ECM proteins, we and others have reported the development of decellularization and ECM-enrichment methods that rely on the extraction of - somewhat more soluble -intracellular proteins [16, [43] [44] [45] [46] . The insolubility of ECM proteins is, however, a challenge for subsequent proteomic analyses; indeed mass-spectrometry pipelines require proteins to be solubilized and then digested into peptides.
ECM protein solubilization
Complete ECM protein solubilization requires reagents in concentrations that are incompatible with mass spectrometry. In addition, a fraction of the extracellular matrix is resistant to solubilizing agents (such as SDS or urea) and would be lost if only solubilized material were carried forward. Therefore, we proposed that crude ECM-enriched samples be denatured, reduced and alkylated, deglycosylated, and digested by a combination of proteases (LysC and trypsin), all without intervening centrifugation, in order to minimize losses of otherwise insoluble materials. Using this approach, we could show that solubilization occurs as a concomitant of protease treatment [16, 43] .
Identification of MS spectra and peptides
ECM proteins, in particular collagens, are known to contain extensive sites of unique posttranslational modifications such as hydroxylated lysines or prolines [47, 48] . It is thus important, when conducting database searches for identification of spectra, to allow for such posttranslational modifications.
Using pipelines combining ECM-enrichment procedures and mass spectrometry, we and others have reported the characterization of the composition of ECMs of several normal and diseased tissues (Table 2) [16, 13, 37, 46, [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] . As expected, these studies revealed the presence of largely ubiquitously expressed ECM proteins but also identified tissuespecific proteins. For example the Önnerfjord laboratory showed that different cartilages have different ECM compositions [58] . Moreover, using an approach combining quantitative and targeted mass spectrometry, they showed that the composition of articular cartilage presents spatial variation and demonstrated that asporin, tenascin-C, thrombospondin-4 and perlecan were the most abundant in the superficial cartilage layer, whereas mimecan and thrombospondin-1 were most abundant in the intermediate layer and aggrecan, osteomodulin, chondroadherin were enriched in deeper layers of articular cartilage. The Mayr laboratory reported the characterization of the cardiac ECM and aortic basement membrane and further identified ECM signatures of ischemia/reperfusion and abdominal aortic aneurysm [52, 55, 56] . Using human melanoma and mammary carcinoma xenografts in mouse, and the ability of mass spectrometry to distinguish human (tumor-derived) protein sequences from their murine (stroma-or host-derived) counterparts, we have demonstrated that both the tumor cells and the stromal cells contribute to the production of the tumor ECM [13, 16] . We have also shown that several ECM proteins differentially expressed between poorly and highly metastatic tumors (including Latent TGFβ Binding Protein 3, LTBP3, and the protein Sushi, Nidogen, and EGF-like Domains 1, SNED1) were causal of a more metastatic phenotype [13] . Furthermore, the comparison of the matrisomes of normal and paired tumor samples identified consistent differences in the ECMs of (i) primary tumors as compared with normal surrounding tissues, (ii) metastases and the normal tissue in which they develop, and (iii) primary tumors as compared with metastases derived from them [37] . Finally, using both xenografts and human-patientderived samples, we could show that some ECM proteins identified could serve as potential biomarkers for tumor progression, metastasis and survival [13, 37] .
Building an ECM atlas
The large amount of data generated in "omics" studies has prompted researchers to share their data with the scientific community through dedicated repositories such as Gene Expression Omnibus or GEO for transcriptomics data and ProteomeXchange for proteomics data. In fact more and more a Indicates studies for which raw mass spectrometry were made publicly available and used to build the draft of the ECM atlas (see Tables 3 & 4 and Supplementary Table 1) . journals now strongly encourage or even require that the raw data accompanying publications be deposited in public databases.
We sought to build a first draft of an ECM atlas by integrating publicly available mass spectrometry data from studies designed specifically to characterize the global compositions of ECMs (Table 2) . We gathered raw mass spectrometric data from our own group [13, 16, 37] , data on the glomerular basement membrane from the Humphries lab [60] and data on three different ocular basement membranes (retinal vascular basement membrane, lens capsule, inner limiting membrane) from the Balasubramani group [62] . To provide consistent data analysis, all proteomics datasets were re-analyzed using the search pipeline we previously developed and peptides identified with a false discovery rate b 1.6% were assembled into proteins (using a UniProt database) and annotated as being ECM-derived or not (Supplementary Table 1 ) [16] . As the data were acquired on different mass spectrometers, we cannot readily derive quantitative information regarding the relative abundance of each protein across tissues. Nonetheless, this compilation provides a first draft of an ECM atlas.
Compared with the "in silico" matrisome, this study shows that more than 60% of the predicted ECM glycoproteins were detected in one or more tissues (Fig. 3) . Interestingly, several ECM proteins, in particular members of the insulin-like-growth-factorbinding protein family (IGFBP3, IGFBP4, IGFBP5) , members of the CCN family (CTGF and CYR61), thrombospondin-2 (Thbs2), tenascin-N (Tnn) and VWA9 were only detected, so far, in ECM-enriched preparations from tumor samples (colorectal or mammary carcinomas, melanomas) but not in those from normal tissues ( Table 3, Supplementary   Table 1C, 1D ). All the collagen chains were detected in one or more tissues, even though some are often thought to be cartilage-specific (type II and type IX collagens) (Fig. 3 and Table 3 ). Close to 60% of the predicted proteoglycans were detected. We hypothesize that the matrisome proteins not yet detected will be found in other tissues or at different developmental stages. For example, many ECM proteins are known to be exclusively expressed in teeth (such as ameloblastin, amelogenins, dentin sialophosphoprotein) [64] , bones (such as bone gamma-carboxyglutamate (Gla) protein or osteocalcin, integrin-binding sialoprotein), the inner ear (such as the tectorins) or the nervous system [65, 66] . ECM proteins exist in many different isoforms, and the presence or absence of certain spliced domains can change the function of a protein or be indicative of a diseased state. For example, fibronectin can include two fibronectin type III domains, each encoded by one exon (EIIIB and EIIIA), and the expression of the isoforms of fibronectin including one or both exons have been shown to be restricted to stages of development, remodeling tumor vasculature and sites of injuries [67] . Similar results are true for spliced variants of tenascins [68] and other ECM proteins. The protein database UniProt we used to generate this first draft of the ECM atlas includes comprehensive nomenclature and data on protein isoforms. We were thus able to provide isoform information for several of the core matrisome proteins constituting the ECM atlas (see Table 3 and Supplementary Table 1C and 1D) .
The experimental coverage of the predicted matrisome-associated proteins is not as high: 50% of the ECM-affiliated proteins, over 60% of the ECM regulators and only 25% of the secreted factors have been detected in at least one tissue and a large List of ECM glycoproteins, collagens and proteoglycans detected with at least 2 peptides in any of the 14 tissues compiled in the ECM atlas: human glomerular basement membrane, human retinal vascular basement membrane, human inner limiting membrane (eye), human lens capsule, murine lung, murine colon, human colon, human liver, poorly and highly metastatic melanoma and mammary carcinoma xenografts. See Supplementary Table 1C and 1D for details. proportion of these proteins were detected in only one tissue (see lighter bars Fig. 3 and Table 4 and  Supplementary Table 1C and 1E) . Whether this lower coverage and apparent tissue specificity is true or a consequence of the state of current analyses will need to be determined. Indeed, matrisome-associated proteins and, in particular secreted factors and ECM remodeling enzymes, are typically present in lower Table 4 . ECM atlas part II: Matrisome-associated proteins detected by mass spectrometry.
List of ECM-affiliated proteins, ECM regulators and secreted factors detected with at least 2 peptides in any of the 14 tissues compiled in the ECM atlas: human glomerular basement membrane, human retinal vascular basement membrane, human inner limiting membrane (eye), human lens capsule, murine lung, murine colon, human colon, human liver, poorly and highly metastatic melanoma and mammary carcinoma xenografts. See Supplementary Table 1C and 1E for details. stoichiometry and their low abundance may compromise their identification by mass spectrometry. Some proteins apparently specific to a given tissue type may simply be present but in too low abundance in other tissues to be detected. This may be overcome by implementing "targeted" mass spectrometry approaches, which allow focus on the measurement of a subset of proteins suspected or known to be present in a given sample [69, 70] . Matrisome-associated proteins are also likely to be more soluble than core matrisome proteins and could be lost during decellularization. One approach to retrieve information on more soluble proteins would be to profile not only the composition of the insoluble ECM fraction generated by tissue decellularization but also the composition of the intermediate fractions generated during the decellularization process [43, 63] and the soluble components of tissue interstitial fluid. Of course, these intermediate fractions will also be enriched for intracellular components, thus robust data annotations using matrisome lists could assist with delineating which proteins are soluble matrisome proteins and which are contaminants. Finally, when we initially defined the list of matrisome-associated proteins, we wanted to be inclusive and have included entire families of proteins some of which may not be found in close association with core ECM proteins. This may have resulted in an over-prediction and, based on future experiments, we may revise our definition and distinguish more precisely those proteins belonging to the matrisome from those belonging to the secretome (the human protein atlas [71] predicts that over 3000 human genes have a secreted product).
Future directions in ECM research
With the tools and methods now in place, we can postulate and certainly hope that the completion of a human ECM atlas will be achievable within the next few years. We would like to incorporate additional datasets (including the ones listed in Table 2 ) in the atlas if/when they become publicly accessible and we would like to encourage the deposition of all future research data in the public domain.
Time-and spatially-resolved matrisomes
The analysis of the composition of the ECM of tissues has already revealed novel or unsuspected components of the ECM characteristics of a diseased state or causal of a diseased state. Efforts should now focus on obtaining temporally-and spatially-resolved matrisomes. For those interested in the role of the ECM in diseases, we propose that quantitative proteomics will become a method of choice to profile the dynamic changes in the composition of the extracellular matrix that occur during disease progression or during the course of treatment [72] . We hypothesize that this type of study will allow the identification of novel prognostic or diagnostic ECM markers that could assist clinical decisions (see below).
Development of high-throughput approaches to map post-translational modifications of ECM proteins ECM proteins undergo extensive post-translational modifications including hydroxylation, phosphorylation, sulfation, glycosylation, and crosslinking, that can have significant physiological and/or pathological implications [73] . We propose that beyond the profiling of the ECM proteome, the community should aim for broad implementation of novel "omics" approaches such as glycomics [74] [75] [76] to profile the post-translational modifications of ECM proteins.
ECM proteins also undergo proteolytic cleavage and release fragments as part of their physiological (or pathological) turnover. Increased ECM degradation is a hallmark of pathologies such as osteoarthritis, fibrosis, and cancers [12] . ECM protein fragments displaying biological activities are termed matricryptins or matrikines [77] . These fragments are characterized by novel amino-and/or carboxy-terminal extremities and can thus be identified by mass spectrometry. The emergence of degradomics or terminomics approaches [78] offers interesting opportunities for ECM research. In addition, it has been proposed that the identification of cleaved fragments can also serve as proxy for identifying proteases (e.g. MMPs, cathepsins) active in a given tissue [79] .
Translational applications

ECM proteins as biomarkers
Alterations of the extracellular matrix are responsible for, or accompany, the development of pathologies, such as skeletal and articular diseases, cardiovascular diseases, skin diseases, fibrosis and cancers. We have previously shown that comparison of the matrisomes of normal and cancerous tissues can lead to the identification of novel candidate biomarkers [37] . We thus propose that pursuing the effort of characterizing the composition of extracellular matrices could lead to the identification of novel biomarkers for other diseases in addition to cancers. It is worth noting that ECM proteins are particularly favorable candidate biomarkers for immunohistochemically based assays since they are readily accessible, abundant, and laid down in characteristic patterns. Once identified, disease-specific ECM proteins, or protein isoforms could also serve as anchors for imaging molecules (e.g. fluorescent molecules, radiotracers) or therapeutics (e.g. drugs, cytokines, radioisotopes) that could be coupled, for example, to anti-disease-specific ECM protein antibodies, on the model of systems developed in the Neri lab [80, 81] . In addition, proteolytic fragments of ECM proteins can be released in body fluids and could be used as readouts for disease progression or treatment efficiency [82] [83] [84] .
ECM proteins as therapeutic targets
There are successful precedents for inhibiting integrins to treat thrombosis, auto-immune and inflammatory diseases, etc. [85, 86] . However, there are also many unsuccessful examples, including the use of matrix metalloproteinase inhibitors, in clinical trials for cancer patients [87] . In a 2009 review, Järveläinen and colleagues noted that ECM proteins are often ignored in drug discovery efforts [88] . We postulate that this will change and that high-throughput approaches will permit the identification of novel disease-specific ECM proteins and protein isoforms and that the characterization of the molecular mechanisms downstream of these proteins will offer novel therapeutic opportunities. Therapeutic strategies could include (i) targeting ECM protein synthesis or posttranslational modifications, (ii) targeting ECM remodeling (degradation or crosslinking) and (iii) targeting ECM/ECM receptor interactions [88] as well as the antibody-mediated targeting discussed above.
ECM and regenerative medicine
The ECM provides biophysical and biochemical signals that orchestrate organ formation and function and thus should play a central part in tissue engineering strategies [89] . In addition, the ECM is a fundamental component of stem cell niches [90, 91] . In fact, many stem cell markers are ECM receptors (e.g. CD49a-f are integrins α1-6, CD29 is the integrin β1 and Lgr5 is an R-spondin receptor) and laminins have been demonstrated to affect pluripotency and differentiation of stem cells [90] . Tissue engineers have exploited, to varying degrees, aspects of ECM biology, in particular its biomechanical properties (not discussed here), to design novel scaffolds to support tissue regeneration [92] . Allogeneic or xenogeneic ECMs are now being used routinely to aid the reconstruction of a variety of tissues (e.g. urinary bladder, skin) [93] . Whole organ engineering, if successful, should solve the problem of shortage of organs available to patients awaiting transplant. One approach to engineer a whole functional organ (heart, lung) consists in using decellularized organ scaffolds comprising ECM and some (generally unknown) associated materials and repopulating the scaffold with stem cells. However, so far this approach has not yet succeeded in regenerating fully functional organs. This may be in part due to the fact that decellularization results, as shown by mass spectrometry, in the loss of some ECM components and associated growth factors [63, 94, 95] . At the opposite extreme, minimalistic approaches are parsimoniously incorporating features of ECM proteins such as RGD (integrin-binding) peptides or mimics in artificial scaffolds. However, proteomic studies have revealed that the ECMs of tissues are made of 150 + proteins and although reconstructing this complexity may be difficult (and perhaps unnecessary [96] ), we propose that the results of proteomics studies aimed at characterizing in vivo ECMs should be exploited to guide the design of the next generation of bio-inspired scaffolds to support organ regeneration.
Conclusions
The extracellular matrix has long been considered as a structural component of tissue organization. Recognition of the roles of specific ECM receptors and the binding and presentation of secreted growth factors introduced new concepts of how ECM proteins affect cell behavior and the developing understanding of mechanochemical transduction of ECM-derived signals have all combined to implicate ECM in a wide range of biologically and medically important areas [97] . With the recent development of experimental techniques for thorough characterization of ECM composition and of bioinformatic means to exploit that information, we are at an exciting point in ECM research where we can deploy the power of broad-scale genomic, proteomic and other "omic" approaches to provide new insights into development, disease, therapy and regenerative medicine in addition to further fundamental understanding of the enduring fascinating mysteries of ECM biology.
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